Repurposing FDA-approved sulphonamide carbonic anhydrase inhibitors for treatment of Neisseria gonorrhoeae

• Автори: Nader S. Abutaleb (Автор), Ahmed E. M. Elhassanny (Автор), Alessio Nocentini (Автор), Chad S. Hewitt (Автор), Ahmed Elkashif (Автор), Bruce R. Cooper (Автор), Claudiu T. Supuran (Автор), Mohamed N. Seleem (Автор), Daniel P. Flaherty (Автор)
• Формат: Книга
• Опубліковано: Taylor & Francis Group, 2022-01-01T00:00:00Z.
• Предмети: article
• Онлайн доступ: Connect to this object online.

Neisseria gonorrhoeae is a high-priority pathogen of concern due to the growing prevalence of resistance development against approved antibiotics. Herein, we report the anti-gonococcal activity of ethoxzolamide, the FDA-approved human carbonic anhydrase inhibitor. Ethoxzolamide displayed an MIC50, a...